Table 2 Summary of secondary endpoints at baseline and week 48
From: Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease
| Â | Losartan | Placebo | Â | ||||
|---|---|---|---|---|---|---|---|
| Â | Baseline (n = 20) | End of study (n = 16) | Change | Baseline (n = 20) | End of study (n = 18) | Change | p-value |
Right atrial pressure (mmHg) | 4.0 (0.8) | 4.0 (0.6) | -0.1 (1.0) | 4.1 (0.9) | 3.8 (0.0) | -0.4 (1.0) | 0.56 |
Peak tricuspid regurgitant velocity (m/s) | 3.3 (0.3) | 3.2 (0.6) | +0.0 (0.7) | 3.3 (0.4) | 3.5 (0.5) | +0.2 (0.4) | 0.37 |
RV systolic pressure (mmHg) | 46.9 (8.9) | 47.3 (14.5) | +0.7 (16.8) | 47.5 (10.0) | 52.5 (13.4) | +4.7 (10.9) | 0.41 |
LV fractional shortening (%) | 33 (8) | 36 (7) | +2.5 (8.6) | 31 (6) | 32 (9) | +1.8 (9.7) | 0.84 |
RV wall thickness (mm) | 4.1 (0.8) | 4.4 (1.3) | +0.4 (1.1) | 4.0 (0.6) | 4.2 (0.6) | +0.3 (0.6) | 0.69 |